Artículos por temáticas

The therapeutic potential of cannabinoids for movement disorders.

Kluger B, Triolo P, Jones W, Jankovic J.

Mov Disord. 2015 Mar;30(3):313-27. doi: 10.1002/mds.26142. Review.

Movement disorders: Friedreich ataxia today—preparing for the final battle.

De Michele G, Filla A.

Nat Rev Neurol. 2015 Apr;11(4):188-90. doi: 10.1038/nrneurol.2015.33. No abstract available.

Drug-induced movement disorders.

Zádori D, Veres G, Szalárdy L, Klivényi P, Vécsei L.

Expert Opin Drug Saf. 2015 Jun;14(6):877-90. doi: 10.1517/14740338.2015.1032244. Review.

Functional (psychogenic) movement disorders associated with normal scores in psychological questionnaires: A case control study.

van der Hoeven RM, Broersma M, Pijnenborg GH, Koops EA, van Laar T, Stone J, van Beilen M.

J Psychosom Res. 2015 Sep;79(3):190-4. doi: 10.1016/j.jpsychores.2015.06.002.

Translating novel findings of perceptual-motor codes into the neuro-rehabilitation of movement disorders.

Pazzaglia M, Galli G.

Front Behav Neurosci. 2015 Aug 21;9:222. doi: 10.3389/fnbeh.2015.00222.

Pseudocyst of the auricle in patients with movement disorders: report of two patients with ataxia-associated auricular pseudocysts.

Beutler BD, Cohen PR.

Dermatol Pract Concept. 2015 Oct 31;5(4):59-64. doi: 10.5826/dpc.0504a15.

Paroxysmal movement disorders.

Waln O, Jankovic J.

Neurol Clin. 2015 Feb;33(1):137-52. doi: 10.1016/j.ncl.2014.09.014. Review.

[Movement disorders as a prodromal sign in individuals at high risk of psychosis].

van Harten PN, Bakker PR, van Os J.

Tijdschr Psychiatr. 2015;57(2):77-82. Dutch.

Spotlight on movement disorders: What optogenetics has to offer.

Rossi MA, Calakos N, Yin HH.

Mov Disord. 2015 Apr 15;30(5):624-31. doi: 10.1002/mds.26184.

Deep brain stimulation for movement disorders: update on recent discoveries and outlook on future developments.

Mahlknecht P, Limousin P, Foltynie T.

J Neurol. 2015 Nov;262(11):2583-95. doi: 10.1007/s00415-015-7790-8. Review.

Intrathecal Baclofen therapy in Germany: Proceedings of the IAB-Interdisciplinary Working Group for Movement Disorders Consensus Meeting.

Dressler D, Berweck S, Chatzikalfas A, Ebke M, Frank B, Hesse S, Huber M, Krauss JK, Mücke KH, Nolte A, Oelmann HD, Schönle PW, Schmutzler M, Pickenbrock H, Van der Ven C, Veelken N, Vogel M, Vogt T,

J Neural Transm (Vienna). 2015 Nov;122(11):1573-9. doi: 10.1007/s00702-015-1425-1.

Medication-induced acute dystonic reaction: the challenge of diagnosing movement disorders in the intensive care unit.

Digby G, Jalini S, Taylor S.

BMJ Case Rep. 2015 Sep 21;2015. pii: bcr2014207215. doi: 10.1136/bcr-2014-207215.

Is pineal melatonin released in the third ventricle in humans? A study in movement disorders.

Leston J, Harthé C, Mottolese C, Mertens P, Sindou M, Claustrat B.

Neurochirurgie. 2015 Apr-Jun;61(2-3):85-9. doi: 10.1016/j.neuchi.2013.04.004.

Movement disorders in systemic diseases.

Poewe W, Djamshidian-Tehrani A.

Neurol Clin. 2015 Feb;33(1):269-97. doi: 10.1016/j.ncl.2014.09.015. Review.

[The genetics of antipsychotic-related movement disorders].

Bakker PR, van Os J, van Harten PN.

Tijdschr Psychiatr. 2015;57(2):114-9. Review. Dutch.